electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 83 full-time employees. The company went IPO on 2018-06-22. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
ECOR'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
electroCore, Inc.'in en son EPS'si $-0.37 olup, $-0.62 beklentilerini kazanmamak.
electroCore, Inc. ECOR'ün son çeyrekteki geliri nasıl performans gösterdi?
electroCore, Inc.'in son çeyrek geliri $-0.37
electroCore, Inc.'in gelir tahmini nedir?
7 Wall Street analistine göre, electroCore, Inc.'in gelir tahmini $10.71M ile $8.52M arasında değişmektedir.
electroCore, Inc.'in kazanç kalite puanı nedir?
electroCore, Inc.'in kazanç kalite puanı A-/58.181366'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
electroCore, Inc. kazançlarını ne zaman rapor eder?
electroCore, Inc.'in bir sonraki kazanç raporu 2026-08-04'te bekleniyor